ABBVIE INC

ABBV is the ticker symbol for AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange. The company discovers, develops, and commercializes advanced therapies for serious health conditions. Its product portfolio spans immunology, oncology, neuroscience, and eye care, among other specialties. ABBV generates revenue primarily through the sale of prescription medicines worldwide.

ABBV operates in the pharmaceutical and biotechnology industry, often classified under healthcare. AbbVie focuses on research-driven specialty drugs, including immunology treatments, oncology therapies, and neuroscience medications. The industry is characterized by high research and development costs, regulatory oversight, and patent-dependent revenue cycles.

Recent performance for ABBV is shown in the price chart and performance data on this page. Stock returns can vary based on product sales, pipeline news, and overall market conditions. For the latest percentage changes over different periods, please refer to the live data displayed above.

Evaluating ABBV's valuation typically involves comparing metrics such as the price-to-earnings (P/E) ratio, price-to-sales, and enterprise value-to-EBITDA against peers and its own historical averages. Analysts also consider pipeline strength, patent expirations, and dividend sustainability. The current valuation metrics for ABBV are available in the financial summary on this page.

ABBV can be traded in pre-market and after-hours sessions on U.S. exchanges, though liquidity is often lower and spreads wider than during regular hours. Extended trading allows investors to react to news outside standard market times. For specific session hours and availability, check with your brokerage, and see the trading data on this page for details.

ABBV has a history of paying quarterly dividends to shareholders. The dividend amount and yield change with the stock price and company decisions. For the most current dividend rate, yield, and payment schedule, please refer to the dividend section on this page.